Digipath
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: Foxwoods Man, drkazmd65
Search This Board: 
Last Post: 12/18/2018 10:05:02 AM - Followers: 215 - Board type: Free - Posts Today: 3

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

 

Digipath
CVM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM News: Securities Registration: Employee Benefit Plan (s-8) 11/07/2018 04:59:20 PM
CVM News: Current Report Filing (8-k) 10/23/2018 09:49:02 AM
CVM News: CEL-SCI Receives about $8 Million from Warrant Exercises 10/23/2018 08:30:00 AM
CVM News: Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ... 10/09/2018 02:31:30 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 10/01/2018 10:45:51 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#12411  Sticky Note Vienna, VA, January 3, 2018 -- CEL-SCI Foxwoods Man 01/03/18 08:19:00 AM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#17499   Is it possible to put a "sticky" on sab63090 12/18/18 10:05:02 AM
#17498   yes all high beta stocks are getting pummeled warfaretrader 12/18/18 09:41:26 AM
#17497   I believe something positive can come out. Just Spideyboy 12/18/18 09:24:41 AM
#17496   I've been completely out of this one since warfaretrader 12/17/18 06:57:43 PM
#17495   lol TB ... was wondering whether my english Fosco1 12/17/18 11:32:19 AM
#17494   LC - Your contrarian cryptic posts are getting Trustbaby 12/16/18 09:25:20 PM
#17493   Here is a hint that is probably impossible learning curve 12/16/18 12:58:22 AM
#17492   I’m going to side with the both of learning curve 12/16/18 12:37:09 AM
#17491   Did you feel stronger one way or the pijoe 12/15/18 06:38:04 PM
#17490   I agree but if the results are further William71 12/14/18 05:41:15 PM
#17489   Institutions only hold about 15% of the float William71 12/14/18 05:37:44 PM
#17488   Geert warned at the SHM that there would M_P_J 12/14/18 05:04:23 PM
#17487   Per a conversation I had today with someone sushifishman 12/14/18 04:54:47 PM
#17486   We seem to have seen both...the lack of sab63090 12/14/18 03:19:07 PM
#17485   ridiculous. Low volume means institutions are not trading georgebailey 12/14/18 03:17:35 PM
#17484   I think small volume with a rising stock William71 12/14/18 03:09:29 PM
#17483   Most biotech stocks were very weak today and sab63090 12/13/18 03:30:57 PM
#17482   Why would any intelligent investor short a $3 William71 12/13/18 02:53:08 PM
#17481   Well it was before. ErIsKoffie 12/13/18 02:49:38 PM
#17480   Moving up? Yeah, not so much... kiowawarrior 12/13/18 01:58:17 PM
#17479   With the short interest at an apparant high, RobotDroid 12/13/18 09:47:00 AM
#17478   I wouldn’t bet against that one, especially since Kpauliukonis 12/13/18 09:28:56 AM
#17477   I agree this stuff always gets out everytime. pijoe 12/13/18 09:24:44 AM
#17476   Well the answer to all of this, is ErIsKoffie 12/13/18 09:21:19 AM
#17475   Another thing to remember is that, according to Kpauliukonis 12/13/18 08:51:50 AM
#17474   I hope so. End of phase 3 better pijoe 12/13/18 08:29:59 AM
#17473   Stock is moving up. ErIsKoffie 12/13/18 07:34:50 AM
#17472   Fox You know what he's all about! sea alice 12/12/18 07:13:21 PM
#17471   Holy crap...I was asking a serious question and Foxwoods Man 12/12/18 03:39:02 PM
#17470   SHOOT THE MESSENGER? yankeesnyc27 12/12/18 03:32:51 PM
#17469   Would not the short report numbers suggest that PARker1703 12/12/18 02:34:02 PM
#17468   This is a PARTIAL cut & past of yankeesnyc27 12/12/18 02:19:34 PM
#17467   Date..... Short Volume Total Volume Short Percent Foxwoods Man 12/12/18 02:09:03 PM
#17466   IS DAILY SHORTING REPORTING IMPORTANT?? yankeesnyc27 12/12/18 01:32:39 PM
#17465   Remember those warrant buys recently by Geert? sab63090 12/12/18 12:37:32 PM
#17464   It's been a long time to see this PARker1703 12/12/18 12:06:29 PM
#17463   https://stockprice.com/stock-market-sectors/biotechnology-sector/where-is-the-ca RobotDroid 12/12/18 08:59:54 AM
#17462   Today's short volume almost 80% and we closed Trustbaby 12/11/18 09:31:55 PM
#17461   Another day of no news on P3. Makes cvm101 12/10/18 04:19:26 PM
#17460   Yep, its like a coiled snake, kinda..if news RobotDroid 12/10/18 03:27:26 PM
#17459   If we were to get any significant buying cvm101 12/10/18 01:15:15 PM
#17458   Must be getting closer as no sells, no RobotDroid 12/10/18 10:53:46 AM
#17457   Correct. Clarification never hurts. We were making the learning curve 12/05/18 02:35:56 AM
#17455   I understand the way futile was being used. pijoe 12/04/18 05:55:43 AM
#17454   I think you missed my point or I learning curve 12/04/18 03:08:14 AM
#17453   I said shining was tanking? learning curve 12/04/18 03:03:31 AM
#17452   Yeah, regardless of the accuracy of said analysis, RobotDroid 12/03/18 07:07:11 PM
#17451   I am a long term (and long time) cvm101 12/03/18 04:40:24 PM
#17450   The devils in the details. RobotDroid 12/03/18 03:57:00 PM
#17449   Ok - breathe deeply - relax - this cvm101 12/03/18 03:52:05 PM
PostSubject